Compare AbCellera Biologics Inc (ABCL) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Sony Group Corp — how do they compare? AbCellera Biologics Inc trades at $9.1 (market cap $2.85B), while Sony Group Corp trades at $23.58 (market cap $139.99B). The key difference: Sony Group Corp is far larger — about 49.1× AbCellera Biologics Inc's market cap, and Sony Group Corp pays a 0.67% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SONY | |
|---|---|---|
Market Cap | $2.85B | $139.99B |
Sector | Health | Technology |
52-Week High | $9.76 | $30.26 |
52-Week Low | $2.78 | $19.32 |
Enterprise Value | $2.45B | $137.89B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Sony stock trades at $23.46, up 1.56% with bullish technical indicators and strong analyst support. The company shows solid revenue growth with $12.96T in 2025 sales and improved profitability, though 2026 projections indicate potential margin pressure. Recent catalysts include the record-breaking Spider-Man film performance and a $6.3B joint venture with TSMC for next-generation image sensors, positioning Sony for continued entertainment and technology leadership.
Sony presents a compelling investment case with strong entertainment franchises and technological innovation, though investors should monitor execution risks in the gaming transition and potential margin compression. Wall Street remains overwhelmingly bullish with 11 buy ratings and a 29.75% upside potential, but the stock faces challenges from currency volatility and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
